Related references
Note: Only part of the references are listed.Small Molecule Inhibitors of the PCSK9 center dot LDLR Interaction
Jam Taechalertpaisarn et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2018)
Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists
Yingnan Zhang et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2017)
Exploring Protein-Peptide Recognition Pathways Using a Supervised Molecular Dynamics Approach
Veronica Salmaso et al.
STRUCTURE (2017)
Investigations on the hypocholesterolaemic activity of LILPKHSDAD and LTFPGSAED, two peptides from lupin β-conglutin: Focus on LDLR and PCSK9 pathways
Chiara Zanoni et al.
JOURNAL OF FUNCTIONAL FOODS (2017)
Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists
Yingnan Zhang et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2017)
Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives
Alberico Luigi Catapano et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2017)
Attacking the supply wagons to starve cancer cells to death
Elizabeth M. Selwan et al.
FEBS LETTERS (2016)
Disrupting the PCSK9/LDLR protein-protein interaction by an imidazole-based minimalist peptidomimetic
Mattia Stucchi et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2016)
Lupin protein exerts cholesterol-lowering effects targeting PCSK9: From clinical evidences to elucidation of the in vitro molecular mechanism using HepG2 cells
Carmen Lammi et al.
JOURNAL OF FUNCTIONAL FOODS (2016)
Lupin Peptides Modulate the Protein-Protein Interaction of PCSK9 with the Low Density Lipoprotein Receptor in HepG2 Cells
Carmen Lammi et al.
SCIENTIFIC REPORTS (2016)
Peptide therapeutics: current status and future directions
Keld Fosgerau et al.
DRUG DISCOVERY TODAY (2015)
A simple and high-throughput in-cell Western assay using HepG2 cell line for investigating the potential hypocholesterolemic effects of food components and nutraceutics
Carmen Lammi et al.
FOOD CHEMISTRY (2015)
ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB
James A. Maier et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2015)
Reducing LDL with PCSK9 Inhibitors - The Clinical Benefit of Lipid Drugs
Brendan M. Everett et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Inhibition of PCSK9 Transcription by Berberine Involves Down-regulation of Hepatic HNF1 α Protein Expression through the Ubiquitin-Proteasome Degradation Pathway
Bin Dong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor
Yingnan Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Binding Free Energy Calculations for Lead Optimization: Assessment of Their Accuracy in an Industrial Drug Design Context
Nadine Homeyer et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2014)
Validation of High-Throughput Genotoxicity Assay Screening Using γH2AX In-Cell Western Assay on HepG2 Cells
Laure Khoury et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2013)
Assessing the Performance of MM/PBSA and MM/GBSA Methods. 3. The Impact of Force Fields and Ligand Charge Models
Lei Xu et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2013)
Applying Physics-Based Scoring to Calculate Free Energies of Binding for Single Amino Acid Mutations in Protein-Protein Complexes
Hege Beard et al.
PLOS ONE (2013)
Peptides and peptide conjugates: therapeutics on the upward path
Verena M. Ahrens et al.
FUTURE MEDICINAL CHEMISTRY (2012)
The Normal-Mode Entropy in the MM/GBSA Method: Effect of System Truncation, Buffer Region, and Dielectric Constant
Samuel Genheden et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2012)
MMPBSA.py: An Efficient Program for End-State Free Energy Calculations
Bill R. Miller et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2012)
Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations
Tingjun Hou et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2011)
Design of novel α7-subtype-preferring nicotinic acetylcholine receptor agonists: Application of docking and MM-PBSA computational approaches, synthetic and pharmacological studies
Giovanni Grazioso et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide
LiXin Shan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
David Cunningham et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2007)
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
Mark J. Graham et al.
JOURNAL OF LIPID RESEARCH (2007)
Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: Mechanism for binding and drug resistance
Tingjun Hou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Molecular biology of PCSK9: its role in LDL metabolism
Jay D. Horton et al.
TRENDS IN BIOCHEMICAL SCIENCES (2007)
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice
Thomas A. Lagace et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Unraveling the importance of protein-protein interaction: Application of a computational alanine-scanning mutagenesis to the study of the IgG1 streptococcal protein G (C2 fragment) complex
Irina S. Moreira et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2006)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults
EE Calle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models
PA Kollman et al.
ACCOUNTS OF CHEMICAL RESEARCH (2000)
Share Paper
